vilzemetkib   Click here for help

GtoPdb Ligand ID: 13220

Synonyms: Example 6 [US20120123126] [1]
Compound class: Synthetic organic
Comment: The chemical structure for vilzemetkib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as an hepatocyte growth factor receptor (c-Met) inhibitor with proposed antineoplastic action. The structure is claimed in patents including some filed by Advenchen laboratories and the Chia Tai Tianqing Pharmaceutical Group. It is likely that vilzemetkib is Advenchen's lead oral c-Met inhibitor AL2846.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 14
Topological polar surface area 110.28
Molecular weight 642.69
XLogP 4.14
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC1=CC2=C(C=C1OCC3(CC3)NC4CCCC4)N=CC=C2OC5=CC=C(C=C5F)NC(=O)C6(CC6)C(=O)NC7=CC=C(C=C7)F
Isomeric SMILES COC1=C(OCC2(CC2)NC3CCCC3)C=C4N=CC=C(OC5=C(F)C=C(NC(=O)C6(CC6)C(=O)NC7=CC=C(F)C=C7)C=C5)C4=C1
InChI InChI=1S/C36H36F2N4O5/c1-45-31-19-26-28(20-32(31)46-21-35(13-14-35)42-24-4-2-3-5-24)39-17-12-29(26)47-30-11-10-25(18-27(30)38)41-34(44)36(15-16-36)33(43)40-23-8-6-22(37)7-9-23/h6-12,17-20,24,42H,2-5,13-16,21H2,1H3,(H,40,43)(H,41,44)
InChI Key IXDALXNUFGTEMF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
AL2846 is an active clinical candidate in a range of trials in patients with advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05745363 Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer Phase 1/Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05815862 Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05011019 A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis Phase 1/Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT05922345 Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. Phase 3 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd.